NVAX:NSD-Novavax Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 19.40

Change

+0.80 (+4.30)%

Market Cap

USD 1.42B

Volume

3.11M

Avg Analyst Target

USD 38.00 (+95.88%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


NVAX Stock Forecast & Price:
Based on the Novavax Inc stock forecasts from 7 analysts, the average analyst target price for Novavax Inc is USD 38.00 over the next 12 months. Novavax Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Novavax Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Novavax Inc’s stock price was USD 19.40. Novavax Inc’s stock price has changed by -3.19% over the past week, -36.16% over the past month and -89.12% over the last year.

About Novavax Inc (NVAX:NSD)

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two P ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+4.41 (+0.60%)

USD78.72B 14.51 10.54
VRTX Vertex Pharmaceuticals Inc

+3.21 (+1.08%)

USD74.26B 23.71 16.14
MRNA Moderna Inc

+4.68 (+3.87%)

USD47.33B 3.81 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+0.89 (+0.65%)

USD32.73B 3.08 1.40
RPRX Royalty Pharma Plc

+1.48 (+3.68%)

USD27.16B 39.01 19.50
SGEN Seagen Inc

+1.47 (+1.07%)

USD25.24B 55.02 -35.49
ALNY Alnylam Pharmaceuticals Inc

+4.45 (+2.26%)

USD23.62B N/A -31.30
GMAB Genmab AS

+1.65 (+4.88%)

USD20.85B 42.28 3.55
ARGX argenx NV ADR

+18.51 (+5.27%)

USD20.47B N/A -19.78

ETFs Containing NVAX

Symbol Name Weight Mer Price(Change) Market Cap
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+1.34 (+2.24%)

USD0.24B
SFYX SoFi Next 500 0.00 % 0.00 %

+0.45 (+4.19%)

USD0.04B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.30 %

+76.00 (+2.56%)

USD0.36B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.30 %

+7.65 (+3.15%)

USD1.02B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.30 %

+1.48 (+3.09%)

USD1.37B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.00 % 0.45 %

+2.40 (+3.04%)

USD0.70B
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.00 % 0.20 %

+0.20 (+2.40%)

USD0.12B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.30 %

+1.16 (+2.38%)

USD1.37B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.45 %

+1.95 (+2.42%)

USD0.70B
GERM ETFMG Treatments Testing .. 0.00 % 0.68 %

+0.76 (+3.63%)

USD0.02B
BUZZ VanEck Social Sentiment E.. 0.00 % 0.75 %

+0.78 (+6.02%)

USD0.07B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -86.44% 8% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.44% 8% F 7% F
Trailing 12 Months  
Capital Gain -88.59% 12% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.59% 12% F 8% F
Trailing 5 Years  
Capital Gain -16.38% 71% C- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.38% 71% C- 36% F
Average Annual (5 Year Horizon)  
Capital Gain 489.27% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 489.27% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 979.71% 2% F 2% F
Risk Adjusted Return 49.94% 92% A- 84% B
Market Capitalization 1.42B 88% B+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 49.52 3% F 2% F
Price / Cash Flow Ratio 4.41 6% F 32% F
EV/EBITDA -0.37 43% F 54% F
Management Effectiveness  
Return on Equity -898.20% 3% F 2% F
Return on Invested Capital -276.06% 6% F 8% F
Return on Assets -32.71% 39% F 14% F
Debt to Equity Ratio -91.98% 94% A 92% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.37 47% F 37% F
Short Percent 21.83% 5% F 6% F
Beta 1.64 25% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector